Preliminary ﬁndings from the ﬁrst-in-human SOLARA trial of BH-30643, a novel macrocyclic, non-covalent, mutant selective, brain active, OMNI-EGFR inhibitor, in EGFR-mutant NSCLC

Tagrisso (osimertinib) - AstraZeneca

BH-30643 - BlossomHill Therap

https://eppro01.ativ.me/web/page.php?page=IntHtml&project=AACRMT25&id=59323

Alexander Spira1; Hidehito Horinouchi2; Misako Nagasaka3; Divya Gupta4; Jonathan Riess5; Melissa Johnson6; Alexander Philipovskiy7; Lyudmila Bazhenova8; Hiroki Izumi9; Jean Cui10; Diane Wang10; Geoffrey Oxnard10; Alena Zalutskaya10; Xiuning Le11

Oct 13, 2025